Literature DB >> 6343379

Induction of indoleamine 2,3-dioxygenase in alveolar interstitial cells of mouse lung by bacterial lipopolysaccharide.

Y Urade, R Yoshida, H Kitamura, O Hayaishi.   

Abstract

The cellular localization of indoleamine 2,3-dioxygenase was studied in the mouse lung after induction by lipopolysaccharide treatment. No significant indoleamine 2,3-dioxygenase activity was detected in alveolar macrophages and type II epithelial cells, which were recovered by alveolar lavages and trypsin-treatment, respectively. To determine this enzyme activity in other types of lung cells, we prepared monodispersed lung cells (6.5 X 10(7) cells/lung) by incubation with 0.1% collagenase and 0.1% trypsin. In a Percoll isopycnic gradient, the dispersed cells were distributed with two peaks at the densities of 1.040 and 1.080 g/ml. The enzyme activity was recovered exclusively in the lighter fractions. As examined by electron microscopy or more quantitatively by using various marker enzyme activities, endothelial cells (angiotensin-converting enzyme as a marker enzyme of these cells), alveolar interstitial cells (prostaglandin dehydrogenase), type I epithelial cells, type II epithelial cells, alveolar macrophages (beta-glucuronidase), Clara cells (coumarin hydroxylase), and polymorphonuclear leucocytes (arylsulfatase) were distributed with peaks at the densities of 1.033, 1.040, 1.042, 1.045, 1.070, 1.082, and 1.093 g/ml, respectively. The distribution pattern of the indoleamine 2,3-dioxygenase activity exactly coincided with that of alveolar interstitial cells. The localization of this enzyme in alveolar interstitial cells was immunohistochemically confirmed with the anti-indoleamine 2,3-dioxygenase antibody.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6343379

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

Review 1.  Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences.

Authors:  Diwakar Davar; Nathan Bahary
Journal:  Target Oncol       Date:  2018-04       Impact factor: 4.493

Review 2.  Trial watch: IDO inhibitors in cancer therapy.

Authors:  Erika Vacchelli; Fernando Aranda; Alexander Eggermont; Catherine Sautès-Fridman; Eric Tartour; Eugene P Kennedy; Michael Platten; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-12-15       Impact factor: 8.110

3.  Airway epithelial indoleamine 2,3-dioxygenase inhibits CD4+ T cells during Aspergillus fumigatus antigen exposure.

Authors:  Sara A Paveglio; Jenna Allard; Samantha R Foster Hodgkins; Jennifer L Ather; Mieke Bevelander; Jana Mayette Campbell; Laurie A Whittaker LeClair; Sean M McCarthy; Albert van der Vliet; Benjamin T Suratt; Jonathan E Boyson; Satoshi Uematsu; Shizuo Akira; Matthew E Poynter
Journal:  Am J Respir Cell Mol Biol       Date:  2010-01-29       Impact factor: 6.914

4.  The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues.

Authors:  Tsung-Cheng Lin; Ying-Chih Liao; Wen-Tsan Chang; Cheng-Han Yang; Li-Hsin Cheng; Megan Cheng; Hung-Chi Cheng
Journal:  J Vis Exp       Date:  2018-06-16       Impact factor: 1.355

5.  Evidence for presence of kynurenine in lung and brain of neonate hamsters.

Authors:  I M Keith; M S Brownfield
Journal:  Histochemistry       Date:  1985

6.  Antioxidant activities of some tryptophan metabolites: possible implication for inflammatory diseases.

Authors:  S Christen; E Peterhans; R Stocker
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.